^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    4d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1069, Recruiting, Gilead Sciences | Trial completion date: Jun 2028 --> Jan 2029
    Trial completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    5d
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397
    6d
    KEYNOTE-E02: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=352, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Sep 2026 --> Mar 2027
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)
    6d
    Electro-Acupuncture in Lung cancER : EALER Study (clinicaltrials.gov)
    P=N/A, N=424, Not yet recruiting, Guangzhou University of Traditional Chinese Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel
    11d
    Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC (clinicaltrials.gov)
    P1, N=3, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    12d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv) • simmitinib (SYHA1817)
    12d
    Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification (clinicaltrials.gov)
    P2, N=60, Recruiting, Qingdao Central Hospital
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    12d
    2021-ky301: Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=78, Completed, Anhui Provincial Hospital | Recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • KRAS G12C • BRAF V600 • MET exon 14 mutation • KRAS G12
    13d
    OCEANII: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Pierre Fabre Medicament | Trial completion date: Sep 2026 --> Dec 2026
    Trial completion date
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    13d
    A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=720, Not yet recruiting, Shanghai Henlius Biotech
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR expression
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab) • pimurutamab (HLX07)
    13d
    PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC (clinicaltrials.gov)
    P=N/A, N=75, Recruiting, University Hospital, Angers | Not yet recruiting --> Recruiting | Trial completion date: Feb 2028 --> Jun 2028 | Trial primary completion date: Feb 2028 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    1m
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2028 --> Feb 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)